Sustainability, affordability, and equity of corporate drug donations: the case of Malarone.
Saved in:
| Title: | Sustainability, affordability, and equity of corporate drug donations: the case of Malarone. |
|---|---|
| Authors: | Shretta, R, Brugha, R, Robb, A, Snow, R W |
| Source: | Lancet. 5/13/2000, Vol. 355 Issue 9216, p1718-1720. 3p. |
| Subjects: | Drug therapy for malaria, Health policy, Antimalarials, Drugs, Public health & economics, Cost effectiveness, Charities, Industries & economics, Combination drug therapy, Comparative studies, Developing countries, Research methodology, Medical cooperation, Quinone, Research, Evaluation research, Atovaquone, Economics |
| Geographic Terms: | Kenya |
| Abstract: | Considers the implications of corporate drug donations for national drug policies and long-term spending choices within the context of the Malarone Donation Programme in Kenya. Situation in Kenya with a problem of sulphadoxine-pyrimethamine failures in malaria treatment and need for alternative drugs; Sustainability and affordability of the antmalarial treatment; Prerequisites for equitable access to the drug. |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Considers the implications of corporate drug donations for national drug policies and long-term spending choices within the context of the Malarone Donation Programme in Kenya. Situation in Kenya with a problem of sulphadoxine-pyrimethamine failures in malaria treatment and need for alternative drugs; Sustainability and affordability of the antmalarial treatment; Prerequisites for equitable access to the drug. |
|---|---|
| ISSN: | 01406736 |
| DOI: | 10.1016/S0140-6736(00)02251-0 |
